Shire buys developer of cell therapy for peripheral arterial disease

04/13/2012 | American City Business Journals · Fox Business

Shire is purchasing Massachusetts-based biotech firm Pervasis Therapeutics, allowing Shire to add Pervasis' endothelial cell technology to its regenerative medicine unit. Pervasis' experimental drug PVS-10200, being developed as a therapy for peripheral arterial disease, complements Shire's Dermagraft product for diabetic foot ulcers, Shire said.

View Full Article in:

American City Business Journals · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations